← All trials
NCT06790966
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 31, 2025
- Primary completion
- Feb 28, 2029
- Completion date
- Feb 28, 2029
- First posted
- Jan 24, 2025
- Last posted
- Mar 13, 2025
- Enrollment
- 351
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- PDS Biotechnology Corp.Lead sponsor
- PDS Biotechnology Corp.Official
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.